2024
The Hierarchical Taxonomy of Psychopathology in Clinical High Risk for Psychosis: Validation and Extension
Williams T, Williams A, Cowan H, Walker E, Cannon T, Bearden C, Keshavan M, Cornblatt B, Addington J, Woods S, Perkins D, Mathalon D, Cadenhead K, Stone W, Mittal V. The Hierarchical Taxonomy of Psychopathology in Clinical High Risk for Psychosis: Validation and Extension. Journal Of Psychopathology And Clinical Science 2024, 133: 235-244. PMID: 38546628, PMCID: PMC11273326, DOI: 10.1037/abn0000893.Peer-Reviewed Original ResearchConceptsHierarchical Taxonomy of PsychopathologyTaxonomy of PsychopathologyClinical high riskHiTOP modelCHR-PChildhood traumaDimensional models of psychopathologyHierarchical taxonomyModels of psychopathologyAttenuated psychotic symptomsBipolar spectrum disordersObsessive-compulsive disorderCHR-P individualsConfirmatory factor analysisPsychotic symptomsPsychotic disordersComorbid diagnosesHiTOPSpectrum disorderPsychosisPsychopathologySocial functioningSelf-reportSpecific hypothesesTest specific hypotheses
2014
Current status specifiers for patients at clinical high risk for psychosis
Woods SW, Walsh BC, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tarbox SI, Tsuang MT, Walker EF, McGlashan TH. Current status specifiers for patients at clinical high risk for psychosis. Schizophrenia Research 2014, 158: 69-75. PMID: 25012147, PMCID: PMC4152558, DOI: 10.1016/j.schres.2014.06.022.Peer-Reviewed Original ResearchConceptsNorth American Prodromal Longitudinal StudyClinical high-risk syndromeHigh-risk syndromeCurrent clinical statusPsychosis risk syndromeLongitudinal studyClinical high riskPartial remissionFull remissionClinical statusRemission criteriaRisk syndromeProgression criteriaRole functioningPredictive validityHigh riskRemitted patientsRemissionPatientsCurrent statusSyndromeConvergent validityPsychosisStructured interviewsPresent study
2013
Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011
Woods SW, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011. Schizophrenia Research 2013, 148: 99-104. PMID: 23787224, PMCID: PMC3867209, DOI: 10.1016/j.schres.2013.05.019.Peer-Reviewed Original ResearchConceptsMedication use ratesCohort 2High riskCohort 1Alternative treatmentAntipsychotic prescription ratesBaseline antipsychotic useHigh-risk patientsEfficacy of antipsychoticsRate of prescriptionPsychotropic medication useChlorpromazine equivalent doseDuration of treatmentUse ratesNonpsychotic conditionsAntipsychotic dosesMedian ageMedication usePrescription ratesAntipsychotic prescriptionsAntipsychotic useAntipsychotic treatmentPsychotropic medicationsHigh-risk youthPsychiatric disorders
2012
Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.Peer-Reviewed Original ResearchConceptsPilot studyRisk syndromeSyndrome patientsNegative symptomsShort-term pilot studyEffect sizeAdjunctive antipsychotic medicationOpen-label studyPatients meeting criteriaNMDA receptor functionDurability of effectPsychosis risk symptomsGlycine site agonistsGroup effect sizesWeeks of evaluationAntipsychotic medicationSyndrome subjectsPromising effect sizesTreatment needsLarge effect sizesMeeting criteriaCognitive impairmentReduced symptomsReceptor functionSymptoms